Urokinase Plasminogen Activator Receptor–PET with 68Ga-NOTA-AE105: First Clinical Experience with a Novel PET Ligand

Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt

Standard

Urokinase Plasminogen Activator Receptor–PET with 68Ga-NOTA-AE105 : First Clinical Experience with a Novel PET Ligand. / Skovgaard, Dorthe; Persson, Morten; Kjaer, Andreas.

I: PET Clinics, Bind 12, Nr. 3, 2017, s. 311-319.

Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt

Harvard

Skovgaard, D, Persson, M & Kjaer, A 2017, 'Urokinase Plasminogen Activator Receptor–PET with 68Ga-NOTA-AE105: First Clinical Experience with a Novel PET Ligand', PET Clinics, bind 12, nr. 3, s. 311-319. https://doi.org/10.1016/j.cpet.2017.02.003

APA

Skovgaard, D., Persson, M., & Kjaer, A. (2017). Urokinase Plasminogen Activator Receptor–PET with 68Ga-NOTA-AE105: First Clinical Experience with a Novel PET Ligand. PET Clinics, 12(3), 311-319. https://doi.org/10.1016/j.cpet.2017.02.003

Vancouver

Skovgaard D, Persson M, Kjaer A. Urokinase Plasminogen Activator Receptor–PET with 68Ga-NOTA-AE105: First Clinical Experience with a Novel PET Ligand. PET Clinics. 2017;12(3):311-319. https://doi.org/10.1016/j.cpet.2017.02.003

Author

Skovgaard, Dorthe ; Persson, Morten ; Kjaer, Andreas. / Urokinase Plasminogen Activator Receptor–PET with 68Ga-NOTA-AE105 : First Clinical Experience with a Novel PET Ligand. I: PET Clinics. 2017 ; Bind 12, Nr. 3. s. 311-319.

Bibtex

@article{59299ef610c74ee8b902ebab512898d6,
title = "Urokinase Plasminogen Activator Receptor–PET with 68Ga-NOTA-AE105: First Clinical Experience with a Novel PET Ligand",
abstract = "Urokinase plasminogen activator receptor (uPAR) is a key component in proteolysis and extracellular matrix degradation during cancer invasion and metastasis. uPAR overexpression is an important biomarker for aggressiveness in several solid tumors and provides independent clinical information. A recent major breakthrough was obtained with human translation of uPAR PET using 68Ga-NOTA-AE105. Clinical results are encouraging and several large-scale clinical trials are now ongoing. This review focuses on uPAR PET with 68Ga-NOTA-AE105 as a new broadly applicable diagnostic and prognostic imaging biomarker in cancer.",
keywords = "Breast cancer, Invasiveness, Molecular imaging, Oncology, PET, Prognostication, Prostate cancer, Theranostics",
author = "Dorthe Skovgaard and Morten Persson and Andreas Kjaer",
year = "2017",
doi = "10.1016/j.cpet.2017.02.003",
language = "English",
volume = "12",
pages = "311--319",
journal = "P E T Clinics",
issn = "1556-8598",
publisher = "W.B.Saunders Co.",
number = "3",

}

RIS

TY - JOUR

T1 - Urokinase Plasminogen Activator Receptor–PET with 68Ga-NOTA-AE105

T2 - First Clinical Experience with a Novel PET Ligand

AU - Skovgaard, Dorthe

AU - Persson, Morten

AU - Kjaer, Andreas

PY - 2017

Y1 - 2017

N2 - Urokinase plasminogen activator receptor (uPAR) is a key component in proteolysis and extracellular matrix degradation during cancer invasion and metastasis. uPAR overexpression is an important biomarker for aggressiveness in several solid tumors and provides independent clinical information. A recent major breakthrough was obtained with human translation of uPAR PET using 68Ga-NOTA-AE105. Clinical results are encouraging and several large-scale clinical trials are now ongoing. This review focuses on uPAR PET with 68Ga-NOTA-AE105 as a new broadly applicable diagnostic and prognostic imaging biomarker in cancer.

AB - Urokinase plasminogen activator receptor (uPAR) is a key component in proteolysis and extracellular matrix degradation during cancer invasion and metastasis. uPAR overexpression is an important biomarker for aggressiveness in several solid tumors and provides independent clinical information. A recent major breakthrough was obtained with human translation of uPAR PET using 68Ga-NOTA-AE105. Clinical results are encouraging and several large-scale clinical trials are now ongoing. This review focuses on uPAR PET with 68Ga-NOTA-AE105 as a new broadly applicable diagnostic and prognostic imaging biomarker in cancer.

KW - Breast cancer

KW - Invasiveness

KW - Molecular imaging

KW - Oncology

KW - PET

KW - Prognostication

KW - Prostate cancer

KW - Theranostics

U2 - 10.1016/j.cpet.2017.02.003

DO - 10.1016/j.cpet.2017.02.003

M3 - Review

C2 - 28576169

AN - SCOPUS:85017274030

VL - 12

SP - 311

EP - 319

JO - P E T Clinics

JF - P E T Clinics

SN - 1556-8598

IS - 3

ER -

ID: 197803669